Ayan Mohamed Hassan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ayan Mohamed Hassan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Abdullahi Abdi Yusuf
Faculty of Medicine and Surgery, Somali National University, Mogadishu, Somalia
7 shared publications - Deka Ahmed Abdi
Faculty of Medicine and Surgery, Somali National University, Mogadishu, Somalia
7 shared publications - Ayan Ahmed Mohamed
Faculty of Medicine and Surgery, Somali National University, Mogadishu, Somalia
5 shared publications - Khalid Hussein Ulusow
Faculty of Medicine and Surgery, Somali National University, Mogadishu, Somalia
5 shared publications - Aden Mohamed Hirsi
Faculty of Medicine and Health Sciences, Somali National University
3 shared publications - Abdihamid Hirsi Abdulle
Faculty of Medicine and Surgery, Somali National University, Mogadishu, Somalia
2 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 42 (1)
When reproductive care ends: the cardiometabolic continuity gap in PMOS in low- and middle-income countries—a mini-review
- 12 November 2026
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 42 (1)
Open AccessWhen reproductive care ends: the cardiometabolic continuity gap in PMOS in low- and middle-income countries—a mini-review
- Open Access
- 1 November 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-10
Procalcitonin as a Stewardship Checkpoint, Not an Antibiotic Gatekeeper: From Antibiotic Initiation to Discontinuation in Resource-Limited Hospitals
Procalcitonin has emerged as a promising biomarker for antimicrobial stewardship; however, its clinical value differs substantially across the antibiotic treatment pathways. Evidence supporting its use to determine whether antibiotics should be initiated remains limited, particularly in patients with suspected sepsis or physiological instability, in whom a low initial concentration cannot safely exclude serious bacterial infections. Its more consistent value appears after empirical treatment has begun, when serial measurements can support clinical reassessment, de-escalation, shorter treatment duration, and earlier discontinuation of treatment. Nevertheless, procalcitonin thresholds and trends should function as decision-support criteria rather than automatic prescribing rules and must be interpreted alongside clinical trajectory, microbiological findings, imaging, organ recovery, infection type, and adequacy of source control. The implementation of this strategy presents additional challenges in resource-limited hospitals, where test availability, turnaround time, repeated measurement, affordability, clinician adherence, and formal stewardship capacity may be inconsistent. Therefore, introducing procalcitonin as an isolated laboratory test may increase expenditure without meaningfully changing antibiotic use. This Perspective proposes selective procalcitonin use among patients already receiving empirical antibiotics whose need for continued treatment remains uncertain, particularly where timely serial testing and structured 24– 72-hour antibiotic review is feasible. In the absence of these conditions, strengthening basic stewardship practices may provide greater value. Therefore, procalcitonin should function as a targeted checkpoint for reassessment and discontinuation rather than as an independent gatekeeper for antibiotic initiation. Plain Language Summary: Procalcitonin is a blood test that may help doctors decide how long a patient needs to be on antibiotics. However, doctors should not use it alone to decide whether to start antibiotics in patients with suspected sepsis because a low result cannot safely rule out a serious bacterial infection. Procalcitonin appears to be more useful after the initiation of treatment. Doctors can use repeated measurements together with the patient’s clinical improvement, laboratory findings, imaging, and control of the infection source to help decide whether antibiotics can be stopped earlier. Resource-limited hospitals may find this approach difficult to implement. Hospitals need affordable testing, rapid results, access to repeat measurements, and regular antibiotic review so that clinicians can act on the findings. Introducing the test without these systems may increase costs without reducing antibiotic use. Resource-limited hospitals should therefore use procalcitonin selectively for patients already receiving empirical antibiotics when clinicians remain uncertain about the need for continued treatment. Where hospitals cannot provide timely repeat testing and structured antibiotic review, strengthening basic antimicrobial stewardship practices should remain the priority.
- 1 November 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-10
Open AccessProcalcitonin as a Stewardship Checkpoint, Not an Antibiotic Gatekeeper: From Antibiotic Initiation to Discontinuation in Resource-Limited Hospitals
Procalcitonin has emerged as a promising biomarker for antimicrobial stewardship; however, its clinical value differs substantially across the antibiotic treatment pathways. Evidence supporting its use to determine whether antibiotics should be initiated remains limited, particularly in patients with suspected sepsis or physiological instability, in whom a low initial concentration cannot safely exclude serious bacterial infections. Its more consistent value appears after empirical treatment has begun, when serial measurements can support clinical reassessment, de-escalation, shorter treatment duration, and earlier discontinuation of treatment. Nevertheless, procalcitonin thresholds and trends should function as decision-support criteria rather than automatic prescribing rules and must be interpreted alongside clinical trajectory, microbiological findings, imaging, organ recovery, infection type, and adequacy of source control. The implementation of this strategy presents additional challenges in resource-limited hospitals, where test availability, turnaround time, repeated measurement, affordability, clinician adherence, and formal stewardship capacity may be inconsistent. Therefore, introducing procalcitonin as an isolated laboratory test may increase expenditure without meaningfully changing antibiotic use. This Perspective proposes selective procalcitonin use among patients already receiving empirical antibiotics whose need for continued treatment remains uncertain, particularly where timely serial testing and structured 24– 72-hour antibiotic review is feasible. In the absence of these conditions, strengthening basic stewardship practices may provide greater value. Therefore, procalcitonin should function as a targeted checkpoint for reassessment and discontinuation rather than as an independent gatekeeper for antibiotic initiation. Plain Language Summary: Procalcitonin is a blood test that may help doctors decide how long a patient needs to be on antibiotics. However, doctors should not use it alone to decide whether to start antibiotics in patients with suspected sepsis because a low result cannot safely rule out a serious bacterial infection. Procalcitonin appears to be more useful after the initiation of treatment. Doctors can use repeated measurements together with the patient’s clinical improvement, laboratory findings, imaging, and control of the infection source to help decide whether antibiotics can be stopped earlier. Resource-limited hospitals may find this approach difficult to implement. Hospitals need affordable testing, rapid results, access to repeat measurements, and regular antibiotic review so that clinicians can act on the findings. Introducing the test without these systems may increase costs without reducing antibiotic use. Resource-limited hospitals should therefore use procalcitonin selectively for patients already receiving empirical antibiotics when clinicians remain uncertain about the need for continued treatment. Where hospitals cannot provide timely repeat testing and structured antibiotic review, strengthening basic antimicrobial stewardship practices should remain the priority.
- Open Access
- 12 October 2026
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 15 (1)
Species breadth is a preparedness metric: lessons from the 2026 Bundibugyo virus disease outbreak
The rapid, unchecked growth of the 2026 Bundibugyo virus disease outbreak in the Democratic Republic of the Congo (DRC) and Uganda should not be interpreted merely as a consequence of delayed outbr...
- 12 October 2026
- Published by Taylor & Francis in Emerging Microbes & Infections
- Vol. 15 (1)
Open AccessSpecies breadth is a preparedness metric: lessons from the 2026 Bundibugyo virus disease outbreak
The rapid, unchecked growth of the 2026 Bundibugyo virus disease outbreak in the Democratic Republic of the Congo (DRC) and Uganda should not be interpreted merely as a consequence of delayed outbr...
- Open Access
- 8 September 2026
- Published by Elsevier in African Journal of Emergency Medicine
- Vol. 16 (4)
Beyond family donors: building reliable emergency blood access in Somalia
- 8 September 2026
- Published by Elsevier in African Journal of Emergency Medicine
- Vol. 16 (4)
Open AccessBeyond family donors: building reliable emergency blood access in Somalia
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-6
Operationalizing the WHO Blueprint for Fungal Disease and Antifungal Resistance in Fragile Health Systems: Insights from Somalia
The World Health Organization (WHO) Blueprint for Strengthening Responses to Fungal Disease and Antifungal Resistance provides a global framework for improving national responses to fungal diseases and antifungal resistance. However, translating these recommendations into routine practice remains challenging in fragile and resource-constrained health systems, where weak governance, limited laboratory capacity, workforce shortages, constrained financing, and fragile supply chains may hinder implementation. Using Somalia as an illustrative context, this narrative policy commentary examines how such health-system constraints may affect operationalization of the WHO Blueprint. Somalia specific evidence on fungal disease burden and antifungal resistance remains limited; therefore, the country is used as an implementation context rather than as an evaluated fungal disease program. Drawing on the WHO Blueprint, established health-system strengthening concepts, and implementation constraints relevant to fragile settings, we propose a phased approach built around five interconnected priorities: strengthening governance and coordination, expanding laboratory and surveillance capacity, ensuring sustainable access to essential antifungal medicines, developing the health workforce, and integrating fungal disease services within existing health-system platforms. Rather than establishing new vertical programs, fragile health systems should leverage existing antimicrobial-resistance initiatives, laboratory networks, procurement mechanisms, and clinical training structures to improve feasibility and sustainability. Although derived from the Somalia context, these considerations may also be relevant to other settings facing similar resource and system constraints. The success of the WHO Blueprint will ultimately depend on the ability of health systems to adapt global recommendations into feasible and sustainable national action.
- 1 September 2026
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 19, 1-6
Open AccessOperationalizing the WHO Blueprint for Fungal Disease and Antifungal Resistance in Fragile Health Systems: Insights from Somalia
The World Health Organization (WHO) Blueprint for Strengthening Responses to Fungal Disease and Antifungal Resistance provides a global framework for improving national responses to fungal diseases and antifungal resistance. However, translating these recommendations into routine practice remains challenging in fragile and resource-constrained health systems, where weak governance, limited laboratory capacity, workforce shortages, constrained financing, and fragile supply chains may hinder implementation. Using Somalia as an illustrative context, this narrative policy commentary examines how such health-system constraints may affect operationalization of the WHO Blueprint. Somalia specific evidence on fungal disease burden and antifungal resistance remains limited; therefore, the country is used as an implementation context rather than as an evaluated fungal disease program. Drawing on the WHO Blueprint, established health-system strengthening concepts, and implementation constraints relevant to fragile settings, we propose a phased approach built around five interconnected priorities: strengthening governance and coordination, expanding laboratory and surveillance capacity, ensuring sustainable access to essential antifungal medicines, developing the health workforce, and integrating fungal disease services within existing health-system platforms. Rather than establishing new vertical programs, fragile health systems should leverage existing antimicrobial-resistance initiatives, laboratory networks, procurement mechanisms, and clinical training structures to improve feasibility and sustainability. Although derived from the Somalia context, these considerations may also be relevant to other settings facing similar resource and system constraints. The success of the WHO Blueprint will ultimately depend on the ability of health systems to adapt global recommendations into feasible and sustainable national action.
- 18 August 2026
- Published by Taylor & Francis in Traffic Injury Prevention
- p. 1-2
Letter to the editor: Beyond the crash: Tramadol use as an underexplored risk in Somalia’s motorcycle trauma burden
To the Editor,Road traffic injuries remain a major global public health problem, with a disproportionate burden in low- and middle-income countries where motorcycles increasingly serve as essential...
- 18 August 2026
- Published by Taylor & Francis in Traffic Injury Prevention
- p. 1-2
Letter to the editor: Beyond the crash: Tramadol use as an underexplored risk in Somalia’s motorcycle trauma burden
To the Editor,Road traffic injuries remain a major global public health problem, with a disproportionate burden in low- and middle-income countries where motorcycles increasingly serve as essential...
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Nephrology
- Vol. 2026 (1)
Acute Kidney Injury in East Africa in an Era of Converging Renal Stressors: A Multiple‐Hit Narrative Review
Background: Acute kidney injury (AKI) remains an important cause of morbidity and mortality in East Africa, where infectious disease, volume depletion, hemodynamic instability, and nephrotoxic exposure frequently occur in resource‐constrained clinical settings. This review aimed to synthesize regional evidence through a multiple‐hit framework focused on three modifiable renal stressor domains. Methods: A structured narrative review of PubMed, Embase, and Scopus was conducted for peer‐reviewed human studies published from January 2012 to 18 August 2026 across the 18 Eastern African countries defined by the United Nations M49 framework. Eligible studies examined AKI in relation to volume depletion or hemodynamic compromise, infection or inflammatory illness, and/or nephrotoxic exposure. Results: Of 902 records identified, 420 duplicates were removed, 482 records were screened, 66 full‐text reports were assessed, and 45 studies were included. Evidence originated from only six countries: Ethiopia, Uganda, Tanzania, Kenya, Somalia/Somaliland, and Rwanda. Across adult, pediatric, neonatal, obstetric, infectious‐disease, emergency, cardiac, and critical‐care populations, AKI was associated with dehydration, hemorrhage, hypotension, shock, malaria, sepsis and other infections, nephrotoxic medications, iodinated contrast, and traditional or herbal medicines. The most consistently documented pattern was cohort‐level clustering of more than one renal stressor domain within the same clinical populations. Individual‐level coexistence was documented in selected studies, whereas detailed temporal sequencing was uncommon. Most studies assessed exposures separately and rarely examined cumulative effects, exposure timing, or statistical interaction. Conclusion: The currently available evidence from East Africa supports a multiple‐hit perspective as a clinical organizing framework rather than a proven biological or prognostic model. Because the evidence is geographically concentrated, particularly in Ethiopia, Uganda, and Tanzania, these findings should not be interpreted as representative of all East African settings. Recurrent cohort‐level clustering of infectious or inflammatory, hemodynamic, and nephrotoxic stressors was well documented, but patient‐level coexistence and temporal sequence remain incompletely characterized. Prospective multicountry studies with patient‐level temporal data are needed to determine whether the timing, overlap, duration, or combination of these stressors influences AKI severity, recovery, and longer‐term outcomes.
- 1 January 2026
- Published by Wiley in International Journal of Nephrology
- Vol. 2026 (1)
Open AccessAcute Kidney Injury in East Africa in an Era of Converging Renal Stressors: A Multiple‐Hit Narrative Review
Background: Acute kidney injury (AKI) remains an important cause of morbidity and mortality in East Africa, where infectious disease, volume depletion, hemodynamic instability, and nephrotoxic exposure frequently occur in resource‐constrained clinical settings. This review aimed to synthesize regional evidence through a multiple‐hit framework focused on three modifiable renal stressor domains. Methods: A structured narrative review of PubMed, Embase, and Scopus was conducted for peer‐reviewed human studies published from January 2012 to 18 August 2026 across the 18 Eastern African countries defined by the United Nations M49 framework. Eligible studies examined AKI in relation to volume depletion or hemodynamic compromise, infection or inflammatory illness, and/or nephrotoxic exposure. Results: Of 902 records identified, 420 duplicates were removed, 482 records were screened, 66 full‐text reports were assessed, and 45 studies were included. Evidence originated from only six countries: Ethiopia, Uganda, Tanzania, Kenya, Somalia/Somaliland, and Rwanda. Across adult, pediatric, neonatal, obstetric, infectious‐disease, emergency, cardiac, and critical‐care populations, AKI was associated with dehydration, hemorrhage, hypotension, shock, malaria, sepsis and other infections, nephrotoxic medications, iodinated contrast, and traditional or herbal medicines. The most consistently documented pattern was cohort‐level clustering of more than one renal stressor domain within the same clinical populations. Individual‐level coexistence was documented in selected studies, whereas detailed temporal sequencing was uncommon. Most studies assessed exposures separately and rarely examined cumulative effects, exposure timing, or statistical interaction. Conclusion: The currently available evidence from East Africa supports a multiple‐hit perspective as a clinical organizing framework rather than a proven biological or prognostic model. Because the evidence is geographically concentrated, particularly in Ethiopia, Uganda, and Tanzania, these findings should not be interpreted as representative of all East African settings. Recurrent cohort‐level clustering of infectious or inflammatory, hemodynamic, and nephrotoxic stressors was well documented, but patient‐level coexistence and temporal sequence remain incompletely characterized. Prospective multicountry studies with patient‐level temporal data are needed to determine whether the timing, overlap, duration, or combination of these stressors influences AKI severity, recovery, and longer‐term outcomes.